Clinical trials: Anxiety Generalized
Generalized Anxiety Disorder
A Study of JNJ-99245354 (ITI-1284) as an Adjunctive Treatment in Participants With Generalized Anxiety Disorder (GAD) Who Have an Inadequate Response to GAD Treatment
The purpose of this study is to assess if JNJ-99245354 administered once daily works better to reduce anxiety compared to placebo when given as an additional (adjunctive) therapy in participants with generalized anxiety disorder…
- Trial name
- NCT07856420
- Testing
- JNJ-99245354
- Volunteers
- 705 people
- Sponsor
- Intra-Cellular Therapies, Inc.
Generalized Anxiety Disorder
Study of Efficacy and Safety of Vortioxetine (Lu AA21004) in Treating Generalized Anxiety Disorder
The purpose of this study is to evaluate the safety and efficacy of 2.5 mg and 10 mg vortioxetine, once daily (QD), in adults with generalized anxiety disorder.
- Trial name
- NCT00731120
- Testing
- Vortioxetine
- Where
- 40 sites in United States
- Volunteers
- 457 people
- Sponsor
- Takeda
Generalized Anxiety Disorder
Clinical Trial of Shugan Jieyu Capsule in Generalized Anxiety Disorder
This is a randomized double-blind placebo-controlled phase 3 clinical trial to further validate the effectiveness and safety of Shugan Jieyu Capsules in treating generalized anxiety disorder.
- Trial name
- NCT05772104
- Testing
- Shugan Jieyu Capsules
- Where
- China
- Volunteers
- 495 people
- Sponsor
- Sichuan Jishengtang Pharmaceutical Co., Ltd.
Generalized Anxiety Disorder (GAD), Anxiety, Separation
SPD503 in Subjects Aged 6-17 Years With Generalized Anxiety Disorder (GAD), Separation Anxiety Disorder (SAD), or Social Phobia (SoP)
This study will evaluate the safety and tolerability of SPD503 in subjects aged 6-17 years with GAD, SAD, or SoP based on treatment emergent adverse events (TEAEs), vital signs and ECGs.
- Conditions
- Generalized Anxiety Disorder (GAD), Anxiety, Separation, Phobia, Social
- Trial name
- NCT01470469
- Testing
- SPD503 (extended-release Guanfacine hydrochloride)
- Where
- 33 sites in United States
- Volunteers
- 83 people
- Sponsor
- Shire
Generalized Anxiety Disorder
Randomized Trial of Adult Participants With Generalized Anxiety Disorder
The purpose of this study is to compare the efficacy of troriluzole versus placebo in participants with generalized anxiety disorder.
- Trial name
- NCT03829241
- Testing
- Troriluzole
- Where
- 53 sites in United States
- Volunteers
- 881 people
- Sponsor
- Biohaven Pharmaceuticals, Inc.
Anxiety Disorders
Study to Assess the Efficacy and Safety of Levetiracetam for the Treatment of Social Anxiety Disorder (Generalized Type)
Preclinical and clinical findings indicate that LEV has some anxiolytic potential. There is reason to believe that compounds with anxiolytic activity may have broad clinical utility across the anxiety spectrum.
- Trial name
- NCT00612859
- Testing
- levetiracetam
- Volunteers
- 217 people
- Sponsor
- UCB Pharma
Generalized Anxiety Disorder
Study of Pexacerfont (BMS-562086) in the Treatment of Outpatients With Generalized Anxiety Disorder
The purpose of this study is to learn about the safety and efficacy of pexacerfont in outpatients diagnosed with Generalized Anxiety Disorder
- Trial name
- NCT00481325
- Testing
- pexacerfont, escitalopram
- Where
- 51 sites in United States
- Volunteers
- 260 people
- Sponsor
- Bristol-Myers Squibb
Generalized Anxiety Disorder
A Study of MK0777 Gel Extrusion Module (GEM) in the Treatment of Outpatients With Generalized Anxiety Disorder (0777-019)
The study will look at the effectiveness of MK0777 in patients with Generalized Anxiety Disorder.
- Trial name
- NCT00703833
- Testing
- MK0777
- Volunteers
- 51 people
- Sponsor
- Merck Sharp & Dohme LLC
Generalized Anxiety Disorder
Pilot Study of Virtual Reality for Providing Exposure Therapy to Children
Drs. from the Mayo Clinic Rochester will plan and execute a feasibility study of the phase I prototype version of the Virtual Reality exposure therapy system. Dr.
- Trial name
- NCT03208348
- Testing
- Pilot Virtual Reality
- Where
- United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Minnesota HealthSolutions
Anxiety Neuroses, Anxiety States, Neurotic
A Study in Pediatric Participants With Generalized Anxiety Disorder
The purpose of this study is to find out if duloxetine [30-120 milligrams (mg)] given once a day by mouth for 10 weeks to children and adolescents, is better than placebo when treating Generalized Anxiety Disorder (GAD).
- Conditions
- Anxiety Neuroses, Anxiety States, Neurotic, Neuroses, Anxiety
- Trial name
- NCT01226511
- Testing
- Duloxetine
- Where
- 24 sites in United States, Mexico and 1 more
- Volunteers
- 281 people
- Sponsor
- Eli Lilly and Company
Pain, Depression
Study Evaluating Rhapsody Registry in Patients With Depression and Anxiety
The purpose of this study is to assess the prevalence of Major Depression and/or Anxiety Disorder in patients consulting the General Practitioner with acute or chronic painful physical symptoms and to identify risk factors.
- Conditions
- Pain, Depression, Anxiety Disorder
- Trial name
- NCT00241397
- Where
- 91 sites in Belgium
- Volunteers
- 2,560 people
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Generalized Anxiety Disorder
Safety & Efficacy Study of Quetiapine Fumarate (SEROQUEL®) vs. Placebo & Active Control in Generalized Anxiety Disorder
The purpose of this study is to demonstrate that quetiapine SR (SEROQUEL®) is efficacious and safe in the acute treatment of patients with Generalized Anxiety Disorder.
- Trial name
- GOLD (NCT00329446)
- Testing
- Quetiapine Fumarate, Escitalopram oxylate
- Where
- 63 sites in United States
- Volunteers
- 800 people
- Sponsor
- AstraZeneca
Generalized Anxiety Disorder
A 10-week Study Evaluating the Efficacy and Safety of PD 0332334 in Patients With Generalized Anxiety Disorder (2)
This is a 10-week trial that evaluates the efficacy and safety of PD 0332334 in subjects, ages 18 to 65, with generalized anxiety disorder.
- Trial name
- NCT00658372
- Testing
- PD 0332334, Paroxetine
- Where
- 33 sites in United States, Hungary and 2 more
- Volunteers
- 360 people
- Sponsor
- Pfizer
General Anxiety Disorder
Electrical Vestibular Nerve Stimulation (VeNS) as a Treatment for Anxiety in Adolescents
Trial title: A Randomized, Double-blind Sham-controlled Clinical Trial to Evaluate The Efficacy of Electrical Vestibular Stimulation (VeNS), Compared to a Sham Control For The Management Of Anxiety in Adolescents - The Modius…
- Trial name
- NCT06956105
- Testing
- Modius Calm
- Where
- India
- Volunteers
- 60 people
- Sponsor
- Neurovalens Ltd.
Generalized Anxiety Disorder
Safety, Efficacy and Tolerability of Vilazodone in Generalized Anxiety Disorder
The purpose of this study is to evaluate the efficacy, safety and tolerability of vilazodone relative to placebo in the treatment of generalized anxiety disorder (GAD)
- Trial name
- VLZ-MD-05 (NCT01629966)
- Testing
- Vilazodone
- Where
- 37 sites in United States
- Volunteers
- 680 people
- Sponsor
- Forest Laboratories
Generalized Anxiety Disorder
Understanding of Participation Trends Within Generalized Anxiety Disorder Patients Involved in Clinical Trials
Typically, certain demographic groups tend to participate more in medical research. However, there is insufficient research explaining the trial characteristics that influence the involvement of these specific demographics.
- Trial name
- NCT06254157
- Where
- United States
- Volunteers
- 500 people
- Sponsor
- Power Life Sciences Inc.
Anxiety
Probiotics for Anxiety Study
The purpose of this study is to observe the effect of a consumer-grade probiotic capsule called GABA (gamma-aminobutyric acid ) Probiotic ("Study Product"), a probiotic capsule containing Lactiplantibacillus plantarum 815, on…
- Trial name
- NCT06466603
- Testing
- GABA Probiotic Dose 1, GABA Probiotic Dose 2
- Where
- United States
- Volunteers
- 122 people, healthy volunteers welcome
- Sponsor
- Verb Biotics LLC
Anxiety Disorders
Efficacy and Safety Study of Seroquel SR in the Treatment of Generalised Anxiety Disorder
The primary purpose of this study is to evaluate whether treatment with (SEROQUEL SR) quetiapine fumarate sustained release (SR) for 9 weeks compared to placebo will improve elderly patients with generalised anxiety disorder.
- Trial name
- NCT00389064
- Testing
- Quetiapine XR
- Where
- 43 sites in United States, Estonia and 3 more
- Volunteers
- 450 people
- Sponsor
- AstraZeneca
Depression - Major Depressive Disorder, Anxiety
Singula Phase 0.1 Primary Care Pilot
This prospective, single-arm, observational pilot study evaluates a clinical decision support system developed by Singula Health for use in primary care.
- Trial name
- NCT07834684
- Where
- 2 sites in United States
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Singula Health, Inc.
Anxiety Disorders
Efficacy, Safety and Tolerability of XBD173 in Patients With Generalized Anxiety Disorder
This study will test the efficacy, safety and tolerability of XBD173 in the treatment of generalized anxiety disorder in patients.
- Trial name
- NCT00108836
- Testing
- XBD173
- Where
- 23 sites in United States, Canada
- Volunteers
- 400 people
- Sponsor
- Novartis Pharmaceuticals